Minimally Invasive Glaucoma Surgery: A Budget Impact Analysis and Evaluation of Patients’ Experiences, Preferences, and Values
Ontario Health (Quality)
Record ID 32018000463
English
Authors' objectives:
Health Quality Ontario collaborated with the Canadian Agency for Drugs and Technologies in Health (CADTH)1 to complete a health technology assessment to evaluate the clinical effectiveness, safety, cost-effectiveness, patient perspectives and experiences, ethical issues, and implementation issues around minimally invasive glaucoma surgery (MIGS) devices and procedures for adults with glaucoma. As part of this evaluation, Health Quality Ontario completed a budget impact evaluation of MIGS for adults with glaucoma in Ontario and an analysis and evaluation of the experiences, preferences, and values of adults with glaucoma.
Authors' results and conclusions:
Results:
Assuming a slow uptake scenario, the annual budget impact of publicly funding MIGS in Ontario over the next 5 years ranges from $1 million in year 1 to $18 million in year 5. Assuming a fast uptake scenario, the annual budget impact of publicly funding MIGS in Ontario over the next
5 years ranges from $6 million in year 1 to $70 million in year 5. The budget impact varies depending on the proportion of people in each of the three subgroups described above. Introducing a new MIGS billing code may reduce the overall expenditures. Interview participants felt that less invasive surgical procedures, such as MIGS, could control glaucoma progression with minimal side effects and recovery time needed.
Conclusions:
We estimate that publicly funding MIGS in Ontario would result in additional costs over the next 5 years; however, this may depend on the populations using MIGS and if uptake is restricted or controlled. For the people with glaucoma we spoke with, avoiding blindness was their paramount concern, and MIGS was perceived as an effective treatment option with minimal side effects and recovery time required.
Authors' recommendations:
Health Quality Ontario, which is now the Quality business unit at Ontario Health, based on the guidance from the Ontario Health Technology Advisory Committee, recommends against publicly funding minimally invasive glaucoma surgery
Authors' methods:
We analyzed the budget impact of publicly funding MIGS in adults with glaucoma in Ontario. We derived costs from the collaborative health technology assessment.1 We assumed MIGS may be used in three subgroups: (1) MIGS in combination with cataract surgery as a replacement for cataract surgery alone in people with mild to moderate glaucoma; (2) MIGS alone as a replacement for other glaucoma treatments in people with mild to moderate glaucoma; and (3) MIGS (alone or in combination with cataract surgery) to replace filtration surgery (alone or in combination with cataract surgery) in people with advanced to severe glaucoma. We estimated the budget impact over 5 years for two possible uptake scenarios: a slow rate of uptake and a fast rate of uptake. To contextualize the lived experience of glaucoma and treatments for glaucoma, we also interviewed people with glaucoma and family members of people with glaucoma, some of whom had experience with surgical procedures such as MIGS and some of whom did not.
Details
Project Status:
Completed
Year Published:
2019
URL for published report:
https://www.hqontario.ca/evidence-to-improve-care/health-technology-assessment/reviews-and-recommendations/minimally-invasive-glaucoma-surgery
Requestor:
Ontario Health Technology Advisory Committee (OHTAC); Ontario Ministry of Health
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Canada
Province:
Ontario
Pubmed ID:
31942228
MeSH Terms
- Minimally Invasive Surgical Procedures
- Glaucoma
- Cost-Benefit Analysis
- Patient Preference
- Ontario
Keywords
- glaucoma
- minimally invasive surgery
- budget impact analysis
- patient preferences
- patient values
Contact
Organisation Name:
Ontario Health
Contact Address:
525 University Ave, Toronto, ON M5G 2L3
Contact Name:
Nancy Sikich, Director Health Technology Assessment
Contact Email:
oh-hqo_hta@ontariohealth.ca
Copyright:
© Queen’s Printer for Ontario, 2019
The copyright for all Health Quality Ontario and Ontario Health publications is owned by the Queen’s Printer for Ontario. Materials may be reproduced for commercial purposes only under a licence from the Queen’s Printer. For further information or to request a licence to reproduce content, please contact:
Senior Copyright Advisor
Publications Ontario
416-326-5153
copyright@ontario.ca
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.